BACKGROUND: Prostate-particular antigen (PSA) based mostly screening for prostate cancer (PCa) has been shown to scale back prostate specific mortality by 20% in an intention to display screen (ITS) evaluation in a randomised trial (European Randomised Research of Screening for Prostate Cancer ERSPC). 24 hour pharmacy

Forum Role: Member

Topics Started: 0

Replies Created: 0